CaMKI₈ (h₃): 293T Lysate: sc-115424



The Power to Question

BACKGROUND

The Ca²+/calmodulin-dependent protein kinases (CaMKs) comprise a structurally related subfamily of serine/threonine kinases. CaMKl δ (Calcium/calmodulin-dependent protein kinase type 1 δ), also known as CKLiK or CaMK1, is a 385 amino acid protein that localizes to both the nucleus and the cytoplasm and contains one protein kinase domain. Expressed in a variety of tissues with higher expression in polymorphonuclear leukocytes, CaMKl δ functions to catalyze the ATP-dependent phosphorylation of target proteins and is thought to regulate calcium-mediated granulocyte function via a calcium-triggered signaling cascade. CaMKl δ is activated by CaM, which binds to and induces a conformational change in CaMKl δ , thereby allowing CaMKK α and CaMKK β to phosphorylate and, subsequently activate CaMKl δ . Nucleotide polymorphisms in the gene encoding CaMKl δ may increase susceptibility to type 2 diabetes. Two isoforms of CaMK1 δ exist due to alternative splicing events

REFERENCES

- Verploegen, S., et al. 2000. Identification and characterization of CKLiK, a novel granulocyte Ca²⁺/calmodulin-dependent kinase. Blood 96: 3215-3223.
- 2. Hook, S.S., et al. 2001. Ca²⁺/CaM-dependent kinases: from activation to function. Annu. Rev. Pharmacol. Toxicol. 41: 471-505.
- Online Mendelian Inheritance in Man, OMIM™. 2002. Johns Hopkins University, Baltimore, MD. MIM Number: 607957. World Wide Web URL: http://www.ncbi.nlm.nih.gov/omim/
- Ishikawa, Y., et al. 2003. Identification and characterization of novel components of a Ca²⁺/calmodulin-dependent protein kinase cascade in HeLa cells. FEBS Lett. 550: 57-63.
- 5. Verploegen, S., et al. 2005. Characterization of the role of CaMKI-like kinase (CKLiK) in human granulocyte function. Blood 106: 1076-1083.
- 6. Grarup, N., et al. 2008. Association testing of novel type 2 diabetes risk alleles in the JAZF1, CDC123/CAMK1D, TSPAN8, THADA, ADAMTS9, and NOTCH2 loci with Insulin release, Insulin sensitivity, and obesity in a population-based sample of 4,516 glucose-tolerant middle-aged Danes. Diabetes 57: 2534-2540.
- 7. Staiger, H., et al. 2008. Novel meta-analysis-derived type 2 diabetes risk loci do not determine prediabetic phenotypes. PLoS ONE 3: e3019.
- Zeggini, E., et al. 2008. Meta-analysis of genome-wide association data and large-scale replication identifies additional susceptibility loci for type 2 diabetes. Nat. Genet. 40: 638-645.

CHROMOSOMAL LOCATION

Genetic locus: CAMK1D (human) mapping to 10p13.

PRODUCT

CaMKl δ (h3): 293T Lysate represents a lysate of human CaMKl δ transfected 293T cells and is provided as 100 μ g protein in 200 μ l SDS-PAGE buffer.

RESEARCH USE

For research use only, not for use in diagnostic procedures.

APPLICATIONS

CaMKI δ (h3): 293T Lysate is suitable as a Western Blotting positive control for human reactive CaMKI δ antibodies. Recommended use: 10-20 μ I per lane


Control 293T Lysate: sc-117752 is available as a Western Blotting negative control lysate derived from non-transfected 293T cells.

CaMKI\u03b8 (C-9): sc-374028 is recommended as a positive control antibody for Western Blot analysis of enhanced human CaMKI\u03b8 expression in CaMKI\u03b8 transfected 293T cells (starting dilution 1:100, dilution range 1:100-1:1,000).

RECOMMENDED SUPPORT REAGENTS

To ensure optimal results, the following support reagents are recommended: 1) Western Blotting: use m-lgG κ BP-HRP: sc-516102 or m-lgG κ BP-HRP (Cruz Marker): sc-516102-CM (dilution range: 1:1000-1:10000), Cruz MarkerTM Molecular Weight Standards: sc-2035, UltraCruz® Blocking Reagent: sc-516214 and Western Blotting Luminol Reagent: sc-2048.

DATA



CaMKIò (C-9): sc-374028. Western blot analysis of CaMKIò expression in non-transfected: sc-117752 (A) and human CaMKIò transfected: sc-115424 (B) 293T whole cell lysates.

STORAGE

Store at -20° C. Repeated freezing and thawing should be minimized. Sample vial should be boiled once prior to use. Non-hazardous. No MSDS required.

PROTOCOLS

See our web site at www.scbt.com for detailed protocols and support products.

Santa Cruz Biotechnology, Inc. 1.800.457.3801 831.457.3800 fax 831.457.3801 Europe +00800 4573 8000 49 6221 4503 0 www.scbt.com